Diagnosis of Latent Tuberculosis Infection in Hemodialysis Patients: TST versus T-SPOT.TB
Open Access
- 14 July 2023
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 13 (14) , 2369
Abstract
Hemodialysis (HD) patients should be screened for latent tuberculosis (TB) infection. We aimed to determine the frequency of latent TB infection in HD patients and to compare the effectiveness of the tests used. The files of 56 HD patients followed between 1 January 2021 and 1 October 2022 were retrospectively analyzed. Demographic data, the presence of the Bacillus Calmette-Guerin (BCG) vaccine, whether or not the patients had previously received treatment for TB before, the status of encountering a patient with active TB of patients over 18 years of age, without active tuberculosis and who had a T-SPOT.TB test or a Tuberculin Skin Test (TST) were obtained from the patient files. The presence of previous TB in a posterior–anterior (PA) chest X-ray was obtained by evaluating PA chest X-rays taken routinely. Of the patients, 60.7% (n = 34) were male and their mean age was 60.18 ± 14.85 years. The mean duration of dialysis was 6.43 ± 6.03 years, and 76.8% (n = 43) had 2 BCG scars. The T-SPOT.TB test was positive in 32.1% (n = 18). Only 20 patients (35.7%) had a TST and all had negative results. While the mean age of those with positive T-SPOT.TB results was higher (p = 0.003), the time taken to enter HD was shorter (p = 0.029). T-SPOT.TB test positivity was higher in the group that had encountered active TB patients (p = 0.033). However, no significant difference was found between T-SPOT.TB results according to BCG vaccine, albumin, urea and lymphocyte levels. Although T-SPOT.TB test positivity was higher in patients with a previous TB finding in a PA chest X-ray, there was no statistically significant difference (p = 0.093). The applicability of the TST in the diagnosis of latent TB infection in HD patients is difficult and it is likely to give false-negative results. The T-SPOT.TB test is not affected by the BCG vaccine and immunosuppression. Therefore, using the T-SPOT.TB test would be a more appropriate and practical approach in the diagnosis of latent TB in HD patients.Keywords
This publication has 36 references indexed in Scilit:
- Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort studyThe Lancet Infectious Diseases, 2018
- Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney diseaseJournal of Infection, 2018
- Tst, Quantiferon-tb Gold test and t-spot.Tb test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-tnf therapyTuberk Toraks, 2018
- Tst, Quantiferon-tb Gold test and t-spot.Tb test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-tnf therapyTuberk Toraks, 2018
- Predictors and Prevalence of Latent Tuberculosis Infection in Patients Receiving Long-Term Hemodialysis and Peritoneal DialysisPLOS ONE, 2012
- The Diagnosis of Tuberculosis in Dialysis PatientsSeminars in Dialysis, 2012
- Interferon‐Gamma Release Assays Are a Better Tuberculosis Screening Test for Hemodialysis Patients: A Study and Review of the LiteratureCanadian Journal of Infectious Diseases and Medical Microbiology, 2012
- Risk of Tuberculosis in Dialysis Patients: A Nationwide Cohort StudyPLOS ONE, 2011
- Validity of interferon-γ-release assays for the diagnosis of latent tuberculosis in haemodialysis patientsClinical Microbiology and Infection, 2010
- Evaluation of cut-off values of interferon-gamma-based assays in the diagnosis of M. tuberculosis infection.2008